Abstract
Aim: The aim of this study was the evaluation of S100B prognostic role in nonmetastatic breast cancer patients, excluding confounding factors. Patients & method: 79 breast cancer patients, who fulfilled inclusion and exclusion criteria, were enrolled in the study. Before any adjuvant chemotherapy or surgery, the serum level of S100B was determined. All patients were followed up for 5 years, particularly regarding cancer recurrence and patients’ survival. Results: 42% of the patients experienced no recurrence after 5 years and cumulative risk of recurrence was 0.86. There was no significant correlation between serum level of protein S100B and recurrence rate in 5 years (p = 0.59). Conclusion: According to the results, the serum levels of S100B protein may have no prognostic role in nonmetastatic breast cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.